Jw Sander;

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/498555/publications.pdf

Version: 2024-02-01

		2427	4	1342	
579	39,138	97		173	
papers	citations	h-index		g-index	
587	587	587		23622	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	CITATIONS
1	Epilepsy in adults. Lancet, The, 2019, 393, 689-701.	13.7	1,067
2	Estimation of the burden of active and lifeâ€time epilepsy: A metaâ€analytic approach. Epilepsia, 2010, 51, 883-890.	5.1	1,045
3	Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia, 2011, 52, 2-26.	5.1	836
4	The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet, The, 2011, 378, 1388-1395.	13.7	789
5	Adult epilepsy. Lancet, The, 2006, 367, 1087-1100.	13.7	678
6	The global burden and stigma of epilepsy. Epilepsy and Behavior, 2008, 12, 540-546.	1.7	665
7	Recommendation for a definition of acute symptomatic seizure. Epilepsia, 2010, 51, 671-675.	5.1	657
8	The epidemiology of epilepsy revisited. Current Opinion in Neurology, 2003, 16, 165-170.	3.6	588
9	The Epidemiology of the Comorbidity of Epilepsy in the General Population. Epilepsia, 2004, 45, 1613-1622.	5.1	546
10	Epidemiology of the epilepsies Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 433-443.	1.9	504
11	The psychiatric comorbidity of epilepsy. Acta Neurologica Scandinavica, 2004, 110, 207-220.	2.1	485
12	Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurology, The, 2016, 15, 106-115.	10.2	453
13	Combined analysis of risk factors for SUDEP. Epilepsia, 2011, 52, 1150-1159.	5.1	413
14	MEDICAL SCIENCE. Lancet, The, 1990, 336, 1267-1271.	13.7	388
15	Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology, 2017, 88, 1674-1680.	1.1	384
16	Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms. Nature Reviews Neurology, 2009, 5, 492-504.	10.1	377
17	Incidence of epilepsy. Neurology, 2011, 77, 1005-1012.	1.1	367
18	Some Aspects of Prognosis in the Epilepsies: A Review. Epilepsia, 1993, 34, 1007-1016.	5.1	365

#	Article	IF	CITATIONS
19	Mortality from epilepsy: results from a prospective population-based study. Lancet, The, 1994, 344, 918-921.	13.7	362
20	Infections, inflammation and epilepsy. Acta Neuropathologica, 2016, 131, 211-234.	7.7	348
21	Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet, The, 1995, 346, 140-144.	13.7	339
22	Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nature Communications, 2018, 9, 5269.	12.8	331
23	Sudden Unexpected Death in Epilepsy: A Review of Incidence and Risk Factors. Epilepsia, 2005, 46, 54-61.	5.1	326
24	The natural history of epilepsy: an epidemiological view. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1376-1381.	1.9	325
25	Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5507-5512.	7.1	321
26	Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain, 2006, 129, 1892-1906.	7.6	315
27	The Use of Antiepileptic Drugs-Principles and Practice. Epilepsia, 2004, 45, 28-34.	5.1	312
28	Mortality in epilepsy in the first 11 to 14 years after diagnosis: Multivariate analysis of a long-term, prospective, population-based cohort. Annals of Neurology, 2001, 49, 336-344.	5.3	309
29	Sudden Death in Epilepsy: A Study of Incidence in a Young Cohort with Epilepsy and Learning Difficulty. Epilepsia, 1995, 36, 1187-1194.	5.1	299
30	Prognosis of Epilepsy: A Review and Further Analysis of the First Nine Years of the British National General Practice Study of Epilepsy, a Prospective Population-Based Study. Epilepsia, 1997, 38, 31-46.	5.1	295
31	Predictors of health-related quality of life and costs in adults with epilepsy: A systematic review. Epilepsia, 2011, 52, 2168-2180.	5.1	283
32	The epidemiology of epilepsy revisited. Current Opinion in Neurology, 2003, 16, 165-170.	3.6	282
33	Sudden unexpected death in epilepsy: People with nocturnal seizures may be at highest risk. Epilepsia, 2012, 53, 253-257.	5.1	269
34	Sudden unexpected death in epilepsy: a series of witnessed deaths. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 211-213.	1.9	268
35	Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancet Neurology, The, 2013, 12, 253-263.	10.2	267
36	New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. Epilepsia, 2020, 61, e49-e53.	5.1	251

#	Article	IF	Citations
37	Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations. PLoS Medicine, 2011, 8, e1001122.	8.4	246
38	Mortality of Epilepsy in Developed Countries: A Review. Epilepsia, 2005, 46, 18-27.	5.1	242
39	Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 462-464.	1.9	233
40	Rare Deletions at $16p13.11$ Predispose to a Diverse Spectrum of Sporadic Epilepsy Syndromes. American Journal of Human Genetics, 2010, 86, 707-718.	6.2	231
41	The burden of premature mortality of epilepsy in highâ€income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia, 2017, 58, 17-26.	5.1	228
42	Topiramate and Psychiatric Adverse Events in Patients withâ€fEpilepsy. Epilepsia, 2003, 44, 659-663.	5.1	226
43	Do antiepileptic drugs or generalized tonic–clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia, 2012, 53, 249-252.	5.1	224
44	The long-term risk of premature mortality in people with epilepsy. Brain, 2011, 134, 388-395.	7.6	223
45	Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy. Drug Safety, 2007, 30, 555-567.	3.2	220
46	Incidence and prevalence studies in epilepsy and their methodological problems: a review Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 829-839.	1.9	212
47	Effects of topiramate on cognitive function. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 636-641.	1.9	211
48	Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. Lancet, The, 1991, 337, 406-409.	13.7	210
49	National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet, The, 1990, 336, 1271-1274.	13.7	205
50	Minimally Invasive Craniopuncture Therapy vs. Conservative Treatment for Spontaneous Intracerebral Hemorrhage: Results from a Randomized Clinical Trial in China. International Journal of Stroke, 2009, 4, 11-16.	5.9	184
51	The excitatory amino acid antagonist d-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Research, 1993, 16, 165-174.	1.6	182
52	The National Hospital Seizure Severity Scale: A Further Development of the Chalfont Seizure Severity Scale. Epilepsia, 1996, 37, 563-571.	5.1	178
53	Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. Lancet Neurology, The, 2018, 17, 143-152.	10.2	178
54	The cost of epilepsy in the United Kingdom: An estimation based on the results of two population-based studies. Epilepsy Research, 1994, 18, 249-260.	1.6	177

#	Article	IF	CITATIONS
55	Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurology, The, 2007, 6, 970-980.	10.2	175
56	Cardiac arrhythmias during or after epileptic seizures. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-310559.	1.9	170
57	Epilepsy in older people. Lancet, The, 2020, 395, 735-748.	13.7	170
58	Vigabatrin and psychosis Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 435-439.	1.9	165
59	Neurocysticercosis and epilepsy in developing countries. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 137-143.	1.9	163
60	Progressive neocortical damage in epilepsy. Annals of Neurology, 2003, 53, 312-324.	5.3	163
61	The somatic comorbidity of epilepsy: A weighty but often unrecognized burden. Epilepsia, 2012, 53, 1282-1293.	5.1	160
62	<i>PRRT2</i> gene mutations. Neurology, 2012, 79, 2115-2121.	1.1	159
63	Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research, 1996, 25, 217-224.	1.6	157
64	Postictal generalized electroencephalographic suppression is associated with generalized seizures. Epilepsy and Behavior, 2011, 21, 271-274.	1.7	155
65	A longitudinal study of brain morphometrics using quantitative magnetic resonance imaging and difference image analysis. Neurolmage, 2003, 20, 22-33.	4.2	154
66	Sudden unexpected death in epilepsy. Current Opinion in Neurology, 2012, 25, 201-207.	3.6	154
67	The natural history and prognosis of epilepsy. Epileptic Disorders, 2015, 17, 243-253.	1.3	152
68	Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. BMJ: British Medical Journal, 2002, 325, 1013-1016.	2.3	150
69	CPD — Education and self-assessment The epidemiology of epilepsy: the size of the problem. Seizure: the Journal of the British Epilepsy Association, 2001, 10, 306-316.	2.0	142
70	A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Research, 1990, 6, 221-226.	1.6	141
71	Omega-3 fatty acid supplementation in patients with chronic epilepsy: A randomized trial. Epilepsy and Behavior, 2005, 7, 253-258.	1.7	141
72	The Chalfont Seizure Severity Scale Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 873-876.	1.9	138

#	Article	IF	Citations
73	Suicide in people with epilepsy: How great is the risk?. Epilepsia, 2009, 50, 1933-1942.	5.1	136
74	Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2004, 13, 425-433.	2.0	135
75	Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain, 2010, 133, 2136-2147.	7.6	132
76	A metaâ€analysis of white matter changes in temporal lobe epilepsy as studied with diffusion tensor imaging. Epilepsia, 2012, 53, 659-667.	5.1	131
77	New onset neurologic events in people with COVID-19 in 3 regions in China. Neurology, 2020, 95, e1479-e1487.	1.1	130
78	Prognostic Factors Affecting Long-Term Retention of Topiramate in Patients with Chronic Epilepsy. Epilepsia, 2000, 41, 338-341.	5.1	129
79	An unknown quantityâ€"The worldwide prevalence of epilepsy. Epilepsia, 2014, 55, 958-962.	5.1	128
80	The epidemiology of the epilepsies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 107, 113-133.	1.8	126
81	Mortality in Dravet syndrome: A review. Epilepsy and Behavior, 2016, 64, 69-74.	1.7	126
82	Pathologic cardiac repolarization in pharmacoresistant epilepsy and its potential role in sudden unexpected death in epilepsy: A case–control study. Epilepsia, 2010, 51, 233-242.	5.1	125
83	Surgical treatment for epilepsy: the potential gap between evidence and practice. Lancet Neurology, The, 2016, 15, 982-994.	10.2	124
84	Active convulsive epilepsy in a rural district of Kenya: a study of prevalence and possible risk factors. Lancet Neurology, The, 2008, 7, 50-56.	10.2	121
85	Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China. Lancet Neurology, The, 2006, 5, 46-52.	10.2	120
86	Premature mortality of epilepsy in low―and middle―ncome countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia, 2017, 58, 6-16.	5.1	120
87	Factors Influencing the Incidence of Lamotrigine-Related Skin Rash. Annals of Pharmacotherapy, 1999, 33, 1037-1042.	1.9	118
88	Cause-Specific Mortality in Epilepsy. Epilepsia, 2005, 46, 36-39.	5.1	117
89	Too long or too short? New insights into abnormal cardiac repolarization in people with chronic epilepsy and its potential role in sudden unexpected death. Epilepsia, 2010, 51, 738-744.	5.1	117
90	Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology, 2020, 94, 1032-1037.	1.1	116

#	Article	IF	Citations
91	Cerebral Damage in Epilepsy: A Population-based Longitudinal Quantitative MRI Study. Epilepsia, 2005, 46, 1482-1494.	5.1	114
92	Life expectancy in people with newly diagnosed epilepsy. Brain, 2004, 127, 2427-2432.	7.6	113
93	Disease modification in partial epilepsy. Brain, 2002, 125, 1937-1950.	7.6	108
94	Seizure-associated hippocampal volume loss: A longitudinal magnetic resonance study of temporal lobe epilepsy. Annals of Neurology, 2002, 52, 861-861.	5.3	107
95	The ketogenic and related diets in adolescents and adults-A review. Epilepsia, 2011, 52, 1941-1948.	5.1	103
96	New diagnostic criteria for neurocysticercosis: Reliability and validity. Annals of Neurology, 2016, 80, 434-442.	5.3	102
97	Premature mortality in people with epilepsy in rural China: a prospective study. Lancet Neurology, The, 2006, 5, 823-827.	10.2	101
98	Epilepsy is a neurological and a systemic disorder. Epilepsy and Behavior, 2018, 78, 57-61.	1.7	101
99	Postictal generalized EEG suppression. Neurology, 2013, 81, 1252-1256.	1.1	99
100	Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free nonâ€"proteinâ€bound concentrations. Epilepsia, 2017, 58, 1234-1243.	5.1	99
101	Intronic ATTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2. Nature Communications, 2019, 10, 4920.	12.8	99
102	Prevalence and Pattern of Epilepsy Treatment in Different Socioeconomic Classes in Brazil. Epilepsia, 2007, 48, 880-885.	5.1	98
103	Drowning in people with epilepsy. Neurology, 2008, 71, 578-582.	1.1	98
104	Seizure Aggravation in Idiopathic Generalized Epilepsies. Epilepsia, 2005, 46, 133-139.	5.1	96
105	Are Psychiatric Adverse Events of Antiepileptic Drugs a Unique Entity? A Study on Topiramate and Levetiracetam. Epilepsia, 2007, 48, 2322-2326.	5.1	96
106	Incidence of photosensitive epilepsy: a prospective national study. Electroencephalography and Clinical Neurophysiology, 1995, 95, 260-267.	0.3	95
107	Structural imaging biomarkers of sudden unexpected death in epilepsy. Brain, 2015, 138, 2907-2919.	7.6	95
108	The global burden of epilepsy report: Implications for low- and middle-income countries. Epilepsy and Behavior, 2020, 105, 106949.	1.7	95

#	Article	IF	CITATIONS
109	Prevalence of epilepsy its treatment gap and knowledge, attitude and practice of its population in sub-urban Senegal an ILAE/IBE/WHO study. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 106-111.	2.0	94
110	Forced normalization at the interface between epilepsy and psychiatry. Epilepsy and Behavior, 2002, 3, 303-308.	1.7	91
111	Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction?. Epilepsy and Behavior, 2011, 20, 20-23.	1.7	91
112	Complex partial status epilepticus: a recurrent problem Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 835-837.	1.9	90
113	Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain, 2004, 128, 7-17.	7.6	88
114	From seizures to epilepsy and its substrates: <scp>N</scp> eurocysticercosis. Epilepsia, 2013, 54, 783-792.	5.1	88
115	The heart of epilepsy: Current views and future concepts. Seizure: the Journal of the British Epilepsy Association, 2017, 44, 176-183.	2.0	87
116	Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Currents, 2017, 17, 180-187.	0.8	87
117	Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure: the Journal of the British Epilepsy Association, 2004, 13, 55-57.	2.0	85
118	The potential neurological effect of the COVIDâ€19 vaccines: A review. Acta Neurologica Scandinavica, 2021, 144, 3-12.	2.1	85
119	Psychiatric Comorbidities in People With Epilepsy. Neurology: Clinical Practice, 2021, 11, e112-e120.	1.6	84
120	Screening for depression in people with epilepsy: Comparative study among Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), Hospital Anxiety and Depression Scale Depression Subscale (HADS-D), and Beck Depression Inventory (BDI). Epilepsy and Behavior, 2014, 34, 50-54.	1.7	83
121	Antiepileptic drug treatment in a community health care setting in northern Ecuador: a prospective 12-month assessment. Epilepsy Research, 1993, 14, 237-244.	1.6	81
122	The Long-Term Safety of Antiepileptic Drugs. CNS Drugs, 2013, 27, 435-455.	5.9	81
123	Premature mortality risk in people with convulsive epilepsy: Long followâ€up of a cohort in rural China. Epilepsia, 2013, 54, 512-517.	5.1	81
124	Patients' perspectives on services for epilepsy: a survey of patient satisfaction, preferences and information provision in 2394 people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2000, 9, 551-558.	2.0	80
125	Cause of death and predictors of mortality in a community-based cohort of people with epilepsy. Neurology, 2016, 86, 704-712.	1.1	80
126	Epilepsy in China: major progress in the past two decades. Lancet Neurology, The, 2021, 20, 316-326.	10.2	80

#	Article	lF	CITATIONS
127	A Prospective Study of the Requirement for and the Provision of Epilepsy Surgery in the United Kingdom. Epilepsia, 2003, 44, 673-676.	5.1	79
128	Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 342-349.	1.9	78
129	Pregabalin: A new antiepileptic drug for refractory epilepsy. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 73-78.	2.0	77
130	Temporal trends in the mortality of people with epilepsy: A review. Epilepsia, 2010, 51, 2241-2246.	5.1	77
131	The Limbic System Conception and Its Historical Evolution. Scientific World Journal, The, 2011, 11, 2427-2440.	2.1	77
132	Atypical face shape and genomic structural variants in epilepsy. Brain, 2012, 135, 3101-3114.	7.6	77
133	Neuroimaging in epilepsy. Current Opinion in Neurology, 2018, 31, 371-378.	3.6	77
134	Causes of death among people with convulsive epilepsy in rural West China. Neurology, 2011, 77, 132-137.	1.1	76
135	Talampanel, a New Antiepileptic Drug: Single- and Multiple-dose Pharmacokinetics and Initial 1-Week Experience in Patients with Chronic Intractableâ€fEpilepsy. Epilepsia, 2003, 44, 46-53.	5.1	75
136	Epilepsy Is a Risk Factor for Sudden Cardiac Arrest in the General Population. PLoS ONE, 2012, 7, e42749.	2.5	75
137	Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Research, 2003, 53, 57-64.	1.6	74
138	Suicide and epilepsy. Current Opinion in Neurology, 2009, 22, 174-178.	3.6	74
139	Genome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy. EBioMedicine, 2015, 2, 1063-1070.	6.1	74
140	First seizures associated with playing electronic screen games: A community-based study in Great Britain. Annals of Neurology, 1995, 37, 733-737.	5.3	73
141	Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy and Behavior, 2010, 18, 24-30.	1.7	73
142	The structural consequences of newly diagnosed seizures. Annals of Neurology, 2002, 52, 573-580.	5.3	72
143	Gloal campaign against epilepsy: assessment of a demonstration project in rural China. Bulletin of the World Health Organization, 2008, 86, 964-969.	3.3	72
144	Do alterations in inter-ictal heart rate variability predict sudden unexpected death in epilepsy?. Epilepsy Research, 2009, 87, 277-280.	1.6	71

#	Article	IF	Citations
145	Suicidality in People Taking Antiepileptic Drugs. CNS Drugs, 2009, 23, 281-292.	5.9	71
146	Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure: the Journal of the British Epilepsy Association, 1994, 3, 29-35.	2.0	69
147	The subjective handicap of epilepsy. A new approach to measuring treatment outcome. Brain, 1998, 121, 317-343.	7.6	69
148	Association of Piriform Cortex Resection With Surgical Outcomes in Patients With Temporal Lobe Epilepsy. JAMA Neurology, 2019, 76, 690.	9.0	69
149	The mortality of epilepsy revisited. Epileptic Disorders, 2004, 6, 3-13.	1.3	69
150	Audit of practice in sudden unexpected death in epilepsy (<scp>SUDEP</scp>) post mortems and neuropathological findings. Neuropathology and Applied Neurobiology, 2016, 42, 463-476.	3.2	68
151	Postictal generalized EEG suppression is not associated with periictal cardiac autonomic instability in people with convulsive seizures. Epilepsia, 2013, 54, 523-529.	5.1	67
152	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Epilepsia, 2018, 59, 1727-1739.	5.1	67
153	Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study. Lancet Neurology, The, 2018, 17, 699-708.	10.2	67
154	Development and Validation of a Prognostic Model of Swallowing Recovery and Enteral Tube Feeding After Ischemic Stroke. JAMA Neurology, 2019, 76, 561.	9.0	67
155	Stigma scale of epilepsy: validation process. Arquivos De Neuro-Psiquiatria, 2007, 65, 35-42.	0.8	66
156	The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Research, 1990, 7, 226-229.	1.6	65
157	Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Research, 2002, 48, 217-219.	1.6	64
158	Antiepileptic drugs: generic versus branded treatments. Lancet Neurology, The, 2007, 6, 465-468.	10.2	64
159	The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia, 2009, 50, 1072-1076.	5.1	64
160	The lifelong course of chronic epilepsy: the Chalfont experience. Brain, 2013, 136, 3187-3199.	7.6	64
161	Clinical features, proximate causes, and consequences of active convulsive epilepsy in <pre><scp>A</scp>frica. Epilepsia, 2014, 55, 76-85.</pre>	5.1	64
162	Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia, 2015, 56, 177-183.	5.1	64

#	Article	IF	Citations
163	The Role of Hippocampal Sclerosis in Topiramate-related Depression and Cognitive Deficits in People with Epilepsy. Epilepsia, 2003, 44, 1573-1577.	5.1	63
164	Drug therapy for solitary cysticercus granuloma. Neurology, 2013, 80, 152-162.	1.1	63
165	The Long-Term Use of Gabapentin, Lamotrigine, and Vigabatrin in Patients with Chronic Epilepsy. Epilepsia, 1999, 40, 1439-1445.	5.1	62
166	Premature mortality in active convulsive epilepsy in rural Kenya. Neurology, 2014, 82, 582-589.	1.1	61
167	Psychosocial aspects of epilepsy: a wider approach. BJPsych Open, 2016, 2, 270-274.	0.7	61
168	Nocturnal supervision and SUDEP risk at different epilepsy care settings. Neurology, 2018, 91, e1508-e1518.	1.1	61
169	Diagnostic implications of genetic copy number variation in epilepsy plus. Epilepsia, 2019, 60, 689-706.	5.1	61
170	Refractory juvenile myoclonic epilepsy: a metaâ€analysis of prevalence and risk factors. European Journal of Neurology, 2019, 26, 856-864.	3.3	61
171	An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Research, 1992, 13, 89-92.	1.6	59
172	Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy and Behavior, 2007, 11, 130-132.	1.7	59
173	How refractory is refractory epilepsy? Patterns of relapse and remission in people with refractory epilepsy. Epilepsy Research, 2011, 96, 225-230.	1.6	59
174	Neuropsychological outcomes in epilepsy surgery patients with unilateral hippocampal sclerosis and good preoperative memory function. Epilepsia, 2013, 54, e131-4.	5.1	59
175	Premature mortality in refractory partial epilepsy: does surgical treatment make a difference?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 716-718.	1.9	58
176	Perampanel Serum Concentrations in Adults With Epilepsy. Therapeutic Drug Monitoring, 2016, 38, 358-364.	2.0	58
177	Newer Antiepileptic Drugs. Drug Safety, 1994, 11, 37-67.	3.2	57
178	A Longitudinal Quantitative MRI Study of Community-Based Patients with Chronic Epilepsy and Newly Diagnosed Seizures: Methodology and Preliminary Findings. NeuroImage, 2001, 14, 231-243.	4.2	57
179	Rationale for using intermittent calorie restriction as a dietary treatment for drug resistant epilepsy. Epilepsy and Behavior, 2014, 33, 110-114.	1.7	57
180	Sudden cardiac arrest in people with epilepsy in the community. Neurology, 2015, 85, 212-218.	1.1	56

#	Article	IF	Citations
181	A Large-Scale Study of Epilepsy in Ecuador: Methodological Aspects. Neuroepidemiology, 1992, 11, 74-84.	2.3	55
182	Increased prevalence of ECG markers for sudden cardiac arrest in refractory epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 309-313.	1.9	55
183	Outcome of seizures in the general population after 25â€years: a prospective follow-up, observational cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 843-850.	1.9	55
184	Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 1008-1010.	1.9	54
185	Carbamazepine―and oxcarbazepine―nduced hyponatremia in people with epilepsy. Epilepsia, 2017, 58, 1227-1233.	5.1	54
186	Seizures after Ischemic Stroke: A Matched Multicenter Study. Annals of Neurology, 2021, 90, 808-820.	5. 3	54
187	In Situ Metabolism of Levetiracetam in Blood of Patients with Epilepsy. Epilepsia, 2006, 47, 1818-1821.	5.1	53
188	Caffeine and seizures: A systematic review and quantitative analysis. Epilepsy and Behavior, 2018, 80, 37-47.	1.7	52
189	Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia, 2011, 52, 258-263.	5.1	50
190	Factors affecting seizure outcome after epilepsy surgery: an observational series. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 933-940.	1.9	50
191	Reducing mortality: an important aim of epilepsy management. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 349-351.	1.9	49
192	Long-term risk of developing epilepsy after febrile seizures. Neurology, 2012, 78, 1166-1170.	1.1	49
193	Cortisol fluctuations relate to interictal epileptiform discharges in stress sensitive epilepsy. Brain, 2016, 139, 1673-1679.	7.6	49
194	A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2018, 54, 61-66.	2.0	49
195	A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Research, 1991, 10, 183-190.	1.6	48
196	Febrile Convulsions in 220 Children – Neurological Sequelae at 12 Years Follow-Up. European Neurology, 1999, 41, 179-186.	1.4	48
197	CORTICAL EXCITABILITY AS A POTENTIAL CLINICAL MARKER OF EPILEPSY: A REVIEW OF THE CLINICAL APPLICATION OF TRANSCRANIAL MAGNETIC STIMULATION. International Journal of Neural Systems, 2014, 24, 1430001.	5.2	48
198	Dynamics of convulsive seizure termination and postictal generalized EEG suppression. Brain, 2017, 140, aww322.	7.6	48

#	Article	IF	CITATIONS
199	Information recalled by women taking anti-epileptic drugs for epilepsy: a questionnaire study. Epilepsy Research, 2002, 52, 139-146.	1.6	47
200	The Mortality Associated with Epilepsy, with Particular Reference to Sudden Unexpected Death: A Review. Epilepsia, 1997, 38, S15-9.	5.1	46
201	Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: A single centre evaluation. Epilepsy Research, 2013, 106, 250-256.	1.6	46
202	Microdysgenesis with abnormal cortical myelinated fibres in temporal lobe epilepsy: a histopathological study with calbindin D-28-K immunohistochemistry. Neuropathology and Applied Neurobiology, 2000, 26, 251-257.	3.2	45
203	The long term retention of levetiracetam in a large cohort of patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 101-103.	1.9	45
204	Retinal nerve fiber layer thickness in Vigabatrinâ€exposed patients. Annals of Neurology, 2011, 69, 845-854.	5.3	45
205	The impact of levetiracetam on challenging behavior. Epilepsy and Behavior, 2006, 8, 588-592.	1.7	44
206	Prejudice towards chronic diseases: Comparison among epilepsy, AIDS and diabetes. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 320-323.	2.0	43
207	Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy and Behavior, 2007, 10, 336-339.	1.7	43
208	Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia, 2010, 51, 2500-2502.	5.1	43
209	Serum brainâ€derived neurotrophic factor levels in epilepsy. European Journal of Neurology, 2014, 21, 57-64.	3.3	43
210	Genetic variation in <i>CFH</i> predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology, 2018, 90, e332-e341.	1.1	43
211	Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. Journal of Epilepsy, 1996, 9, 106-112.	0.4	42
212	Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arquivos De Neuro-Psiquiatria, 1996, 54, 47-49.	0.8	42
213	Predictive value of death certification in the case ascertainment of epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1756-1758.	1.9	42
214	Is omega-3 fatty acid deficiency a factor contributing to refractory seizures and SUDEP?. Seizure: the Journal of the British Epilepsy Association, 2004, 13, 104-107.	2.0	42
215	Association between epilepsy and cysticercosis and toxocariasis: A populationâ€based case–control study in a slum in India. Epilepsia, 2012, 53, 2203-2208.	5.1	42
216	Lacosamide Serum Concentrations in Adult Patients With Epilepsy. Therapeutic Drug Monitoring, 2014, 36, 494-498.	2.0	42

#	Article	IF	Citations
217	Partial epilepsy with pericentral spikes: A new familial epilepsy syndrome with evidence for linkage to chromosome 4p15. Annals of Neurology, 2002, 51, 740-749.	5.3	40
218	A High-Performance Liquid Chromatography Assay to Monitor the New Antiepileptic Drug Lacosamide in Patients With Epilepsy. Therapeutic Drug Monitoring, 2010, 32, 448-452.	2.0	40
219	Peripheral leukocyte profile in people with temporal lobe epilepsy reflects the associated proinflammatory state. Brain, Behavior, and Immunity, 2016, 53, 123-130.	4.1	40
220	Overall and cause-specific premature mortality in epilepsy: A systematic review. Epilepsy and Behavior, 2018, 87, 213-225.	1.7	40
221	Certification of deaths attributable to epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 751-752.	1.9	39
222	Vigabatrin and behaviour disturbances. Lancet, The, 1990, 335, 57.	13.7	38
223	The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 632-637.	1.9	38
224	Sulthiame in adults with refractory epilepsy and learning disability: an open trial. Epilepsy Research, 2002, 50, 277-282.	1.6	38
225	Epilepsy stigma perception in an urban area of a limited-resource country. Epilepsy and Behavior, 2007, 11, 25-32.	1.7	38
226	Treatment changes in a cohort of people with apparently drug-resistant epilepsy: an extended follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 810-813.	1.9	38
227	Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis. Epilepsy Research, 2012, 100, 152-156.	1.6	38
228	Prevalence and factors associated with convulsive status epilepticus in Africans with epilepsy. Neurology, 2015, 84, 1838-1845.	1.1	38
229	Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 199-203.	2.0	37
230	The pharmacological treatment of depression in adults with epilepsy. Expert Opinion on Pharmacotherapy, 2008, 9, 3159-3168.	1.8	37
231	Ketogenic dietary therapies for adults with epilepsy: Feasibility and classification of response. Epilepsy and Behavior, 2014, 37, 77-81.	1.7	37
232	Managing antiâ€epileptic drug treatment in adult patients with intellectual disability: a serious conundrum. European Journal of Neurology, 2016, 23, 1152-1157.	3.3	37
233	Evaluating risk to people with epilepsy during the COVID-19 pandemic: Preliminary findings from the COV-E study. Epilepsy and Behavior, 2021, 115, 107658.	1.7	37
234	Assessing the Disease Burden Due to Epilepsy by Disability Adjusted Life Year in Rural China. Epilepsia, 2006, 47, 2032-2037.	5.1	36

#	Article	IF	Citations
235	Mortality and morbidity rates are increased in people with epilepsy: Is stress part of the equation?. Epilepsy and Behavior, 2007, 10, 1-7.	1.7	36
236	Prevalence of convulsive epilepsy and health-related quality of life of the population with convulsive epilepsy in rural areas of Tibet Autonomous Region in China: An initial survey. Epilepsy and Behavior, 2008, 12, 373-381.	1.7	36
237	Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clinical Therapeutics, 2008, 30, 1180-1195.	2.5	36
238	Epidemiology, pathophysiology and putative genetic basis of carbamazepine―and oxcarbazepine―induced hyponatremia. European Journal of Neurology, 2016, 23, 1393-1399.	3. 3	36
239	Priority concerns for people with intellectual and developmental disabilities during the COVID-19 pandemic. BJPsych Open, 2020, 6, e128.	0.7	36
240	COVIDâ€19 vaccine takeâ€up rate and safety in adults with epilepsy: Data from a multicenter study in China. Epilepsia, 2022, 63, 244-251.	5.1	36
241	Acute psychological disorders in patients with epilepsy: a nation-wide study. Epilepsy Research, 1996, 25, 119-131.	1.6	35
242	Teachers perception about epilepsy. Arquivos De Neuro-Psiquiatria, 2007, 65, 28-34.	0.8	35
243	The comorbid relationship between migraine and epilepsy: a systematic review and metaâ€analysis. European Journal of Neurology, 2015, 22, 1038-1047.	3.3	35
244	Sudden unexpected deaths in epilepsy—where are we now?. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 235-238.	2.0	34
245	Clinical and neurophysiologic features of active convulsive epilepsy in rural Kenya: A populationâ€based study. Epilepsia, 2010, 51, 2370-2376.	5.1	34
246	Stigma and epilepsy: The Chinese perspective. Epilepsy and Behavior, 2010, 17, 242-245.	1.7	34
247	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open, 2019, 4, 420-430.	2.4	34
248	Amygdala sclerosis in sudden and unexpected death in epilepsy. Epilepsy Research, 1999, 37, 53-62.	1.6	33
249	Artificial intelligence extension of the OSCARâ€IB criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542.	3.7	33
250	A Pharmacoepidemiologic Study of Factors Influencing the Outcome of Treatment with Lamotrigine in Chronic Epilepsy. Epilepsia, 2001, 42, 1354-1358.	5.1	32
251	No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Research, 2009, 83, 44-51.	1.6	32
252	Can we predict a favourable response to Ketogenic Diet Therapies for drug-resistant epilepsy?. Epilepsy Research, 2013, 106, 1-16.	1.6	32

#	Article	IF	CITATIONS
253	Impaired intracortical inhibition demonstrated in vivo in people with Dravet syndrome. Neurology, 2017, 88, 1659-1665.	1.1	32
254	FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force. Epilepsia Open, 2021, 6, 45-48.	2.4	32
255	The effect of oral flumazenil on interictal epileptic activity: results of a double-blind, placebo-controlled study. Epilepsy Research, 1993, 15, 53-60.	1.6	31
256	Neurological Disease in a Defined Population: The Results of a Pilot Study in Two General Practices. Neuroepidemiology, 1996, 15, 73-82.	2.3	31
257	Knowledge, attitudes, and stigma towards epilepsy in different walks of life: A study in Georgia. Epilepsy and Behavior, 2013, 27, 315-318.	1.7	31
258	Classification of the Epilepsies: Time for a Change?. European Neurology, 1999, 42, 1-10.	1.4	30
259	Phenobarbital: missing in action. Bulletin of the World Health Organization, 2012, 90, 871-871A.	3.3	30
260	Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype. Brain, 2015, 138, 2859-2874.	7.6	30
261	Identifying and mitigating Sudden Unexpected Death in Epilepsy (SUDEP) risk factors. Expert Review of Neurotherapeutics, 2018, 18, 265-274.	2.8	30
262	Effects of carbamazepine and lamotrigine on functional magnetic resonance imaging cognitive networks. Epilepsia, 2018, 59, 1362-1371.	5.1	30
263	The prevalence and treatment gap of epilepsy in Tbilisi, Georgia. Epilepsy Research, 2012, 98, 123-129.	1.6	29
264	Headache and Epilepsy. Current Pain and Headache Reports, 2013, 17, 351.	2.9	29
265	NHS services for epilepsy from the patient's perspective: a survey of primary, secondary and tertiary care access throughout the UK. Seizure: the Journal of the British Epilepsy Association, 2000, 9, 559-565.	2.0	28
266	Primary care treatment of epilepsy with phenobarbital in rural China: Costâ€outcome analysis from the WHO/ILAE/IBE global campaign against epilepsy demonstration project. Epilepsia, 2008, 49, 535-539.	5.1	28
267	Epilepsy surgery in low- and middle-income countries: A scoping review. Epilepsy and Behavior, 2019, 92, 311-326.	1.7	28
268	A comprehensive community epilepsy programme: the Nakuru project. Epilepsy Research, 1991, 8, 252-259.	1.6	27
269	Training the trainers and disseminating information: a strategy to educate health professionals on epilepsy. Arquivos De Neuro-Psiquiatria, 2007, 65, 14-22.	0.8	27
270	Demonstration project on epilepsy in Brazil: situation assessment. Arquivos De Neuro-Psiquiatria, 2007, 65, 5-13.	0.8	27

#	Article	IF	Citations
271	Non-randomized open trial of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic epilepsy. Epilepsy and Behavior, 2012, 23, 370-372.	1.7	27
272	Tetramethylenedisulfotetramine intoxication presenting with de novo Status Epilepticus: A case series. NeuroToxicology, 2012, 33, 207-211.	3.0	27
273	The relation between cortisol and functional connectivity in people with and without stressâ€sensitive epilepsy. Epilepsia, 2018, 59, 179-189.	5.1	27
274	Overview of the Demonstration Projects. Epilepsia, 2002, 43, 34-36.	5.1	26
275	Multicultural challenges in epilepsy. Epilepsy and Behavior, 2011, 20, 428-434.	1.7	26
276	The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. Epilepsy Research, 2011, 96, 39-44.	1.6	26
277	Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia, 2017, 58, 1734-1741.	5.1	26
278	Adverse perinatal events, treatment gap, and positive family history linked to the high burden of active convulsive epilepsy in Uganda: A populationâ€based study. Epilepsia Open, 2017, 2, 188-198.	2.4	26
279	Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center. Epilepsy and Behavior, 2017, 73, 106-110.	1.7	26
280	Decreasing the risk of sudden unexpected death in epilepsy: structured communication of risk factors for premature mortality in people with epilepsy. European Journal of Neurology, 2018, 25, 1121-1127.	3.3	26
281	Under representation of people with epilepsy and intellectual disability in research. PLoS ONE, 2018, 13, e0198261.	2.5	26
282	Demonstration project on epilepsy in Brazil: outcome assessment. Arquivos De Neuro-Psiquiatria, 2007, 65, 58-62.	0.8	26
283	New anti-epileptic drugs. Expert Opinion on Investigational Drugs, 1999, 8, 1497-1510.	4.1	25
284	Differences in the use of health services among people with and without epilepsy in the United Kingdom: socio-economic and disease-specific determinants. Epilepsy Research, 2002, 50, 233-241.	1.6	25
285	Erythrocyte and plasma fatty acid profiles in patients with epilepsy: Does carbamazepine affect omega-3 fatty acid concentrations?. Epilepsy and Behavior, 2008, 12, 317-323.	1.7	25
286	Stigma scale of epilepsy: the perception of epilepsy stigma in different cities in Brazil. Arquivos De Neuro-Psiquiatria, 2008, 66, 471-476.	0.8	25
287	The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Research, 2009, 87, 120-123.	1.6	25
288	Changes in knowledge, attitude, and practice of people with epilepsy and their families after an intervention in rural China. Epilepsy and Behavior, 2009, 16, 76-79.	1.7	25

#	Article	IF	Citations
289	European survey of the level of satisfaction of patients and physicians in the management of epilepsy in general practice. Epilepsy and Behavior, 2010, 19, 36-42.	1.7	25
290	Patterns of Peripapillary Retinal Nerve Fiber Layer Thinning in Vigabatrin-Exposed Individuals. Ophthalmology, 2012, 119, 2152-2160.	5.2	25
291	Suicide risk in people with epilepsy taking antiepileptic drugs. Bipolar Disorders, 2013, 15, 622-627.	1.9	25
292	Longâ€ŧerm outcome of phenobarbital treatment for epilepsy in rural China: A prospective cohort study. Epilepsia, 2013, 54, 537-542.	5.1	25
293	Somatic complications of epilepsy surgery over 25 years at a single center. Epilepsy Research, 2017, 132, 70-77.	1.6	25
294	Epilepsy and driving. BMJ: British Medical Journal, 2005, 331, 60-61.	2.3	24
295	Suicidality in Epilepsy and Possible Effects of Antiepileptic Drugs. Current Neurology and Neuroscience Reports, 2010, 10, 327-332.	4.2	24
296	Longâ€term prognosis of epilepsy, prognostic patterns and drug resistance: a populationâ€based study. European Journal of Neurology, 2016, 23, 1218-1227.	3.3	24
297	Myoclonic epilepsy of late onset in trisomy 21. Arquivos De Neuro-Psiquiatria, 1995, 53, 792-794.	0.8	23
298	Ictal ECG changes in temporal lobe epilepsy. Arquivos De Neuro-Psiquiatria, 1995, 53, 619-624.	0.8	23
299	Sudden unexpected death in epilepsy. Postgraduate Medical Journal, 1999, 75, 706-709.	1.8	23
300	The clinical impact of epilepsy genetics. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 428-430.	1.9	23
301	Impaired mitochondrial energy production: The basis of pharmacoresistance in epilepsy. Medical Hypotheses, 2011, 77, 536-540.	1.5	23
302	The impact of age on lamotrigine and oxcarbazepine kinetics: A historical cohort study. Epilepsy and Behavior, 2013, 29, 217-221.	1.7	23
303	Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: Prevalence and clinical characteristics. Epilepsy Research, 2015, 115, 55-57.	1.6	23
304	Genomeâ€wide association study: Exploring the genetic basis for responsiveness to ketogenic dietary therapies for drugâ€resistant epilepsy. Epilepsia, 2018, 59, 1557-1566.	5.1	23
305	The association between systemic autoimmune disorders and epilepsy and its clinical implications. Brain, 2021, 144, 372-390.	7.6	23
306	Levetiracetam and Partial Seizure Subtypes: Pooled Data from Three Randomized, Placebo ontrolled Trials. Epilepsia, 2003, 44, 1585-1587.	5.1	22

#	Article	IF	CITATIONS
307	Clinical features of convulsive status epilepticus: a study of 220 cases in western China. European Journal of Neurology, 2009, 16, 444-449.	3.3	22
308	Generic substitution of antiepileptic drugs. Expert Review of Neurotherapeutics, 2010, 10, 1887-1898.	2.8	22
309	Electroencephalographic features of convulsive epilepsy in Africa: A multicentre study of prevalence, pattern and associated factors. Clinical Neurophysiology, 2016, 127, 1099-1107.	1.5	22
310	Magnitude and factors associated with nonadherence to antiepileptic drug treatment in Africa: A crossâ€sectional multisite study. Epilepsia Open, 2017, 2, 226-235.	2.4	22
311	Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia, 2020, 61, 657-666.	5.1	22
312	Sudden Unexpected Death in Epilepsy. Neurology, 2021, 96, e2627-e2638.	1.1	22
313	Incidence, Remission and Mortality of Convulsive Epilepsy in Rural Northeast South Africa. PLoS ONE, 2015, 10, e0129097.	2.5	22
314	Comparing the cost of epilepsy across eight European countries. Epilepsy Research, 2001, 43, 89-95.	1.6	21
315	Cognitive and mood effects of phenobarbital treatment in people with epilepsy in rural China: a prospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1139-1144.	1.9	21
316	Management of chronic epilepsy. BMJ, The, 2012, 345, e4576-e4576.	6.0	21
317	Suicide and epilepsy: do antiepileptic drugs increase the risk?. Expert Opinion on Drug Safety, 2015, 14, 553-558.	2.4	21
318	Perampanel in the general population and in people with intellectual disability: Differing responses. Seizure: the Journal of the British Epilepsy Association, 2017, 49, 30-35.	2.0	21
319	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics, 2020, 21, 325-335.	1.3	21
320	Headache in people with epilepsy. Nature Reviews Neurology, 2021, 17, 529-544.	10.1	21
321	Felbamate as Add-On Therapy. European Neurology, 1996, 36, 146-148.	1.4	20
322	The epilepsy nurse specialist at a tertiary care hospitalâ€"improving the interface between primary and tertiary care. Seizure: the Journal of the British Epilepsy Association, 2002, 11, 494-499.	2.0	20
323	Change in Stroke Incidence from a Population-Based Intervention Trial in Three Urban Communities in China. Neuroepidemiology, 2007, 28, 155-161.	2.3	20
324	Stigma and attitudes on epilepsy a study: with secondary school students. Arquivos De Neuro-Psiquiatria, 2007, 65, 49-54.	0.8	20

#	Article	IF	Citations
325	A historical perspective on the mortality associated with chronic epilepsy. Acta Neurologica Scandinavica, 1997, 96, 138-141.	2.1	20
326	An acidosis-sparing ketogenic (ASK) diet to improve efficacy and reduce adverse effects in the treatment of refractory epilepsy. Epilepsy and Behavior, 2017, 74, 15-21.	1.7	20
327	Acute encephalopathy with vigabatrin. Lancet, The, 1993, 342, 619.	13.7	19
328	Epilepsy and Recreational Scuba Diving: An Absolute Contraindication or Can There Be Exceptions? A Call for Discussion. Epilepsia, 2007, 48, 851-858.	5.1	19
329	Can slow breathing exercises improve seizure control in people with refractory epilepsy? A hypothesis. Epilepsy and Behavior, 2010, 18, 331-334.	1.7	19
330	Vigabatrin therapy for refractory complex partial seizures: review of major European trials. Acta Neurologica Scandinavica, 2011, 124, 16-28.	2.1	19
331	Burden of epilepsy in rural <scp>K</scp> enya measured in disabilityâ€adjusted life years. Epilepsia, 2014, 55, 1626-1633.	5.1	19
332	Interleukin- $1\hat{l}^2$ plasma levels are associated with depression in temporal lobe epilepsy. Epilepsy and Behavior, 2015, 53, 131-134.	1.7	19
333	The long-term course of temporal lobe epilepsy: From unilateral to bilateral interictal epileptiform discharges in repeated video-EEG monitorings. Epilepsy and Behavior, 2017, 68, 17-21.	1.7	19
334	Dealing with the storm: An overview of seizure precipitants and spontaneous seizure worsening in drug-resistant epilepsy. Epilepsy and Behavior, 2019, 97, 212-218.	1.7	19
335	Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries. Nature Reviews Neurology, 2020, 16, 333-345.	10.1	19
336	Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review. Epilepsy and Behavior, 2020, 106, 107043.	1.7	19
337	Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia, 2017, 58, 1524-1532.	5.1	19
338	Longâ€term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program. Epilepsia, 2022, 63, 139-149.	5.1	19
339	The neurological founding fathers of the National Society for Epilepsy and of the Chalfont Centre for Epilepsy Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 599-604.	1.9	18
340	Male Monozygotic Twins Discordant for Periventricular Nodular Heterotopia and Epilepsy. Epilepsia, 1999, 40, 248-250.	5.1	18
341	Training medical students to improve the management of people with epilepsy. Arquivos De Neuro-Psiquiatria, 2007, 65, 23-27.	0.8	18
342	Incidence of convulsive epilepsy in a rural area in <scp>K</scp> enya. Epilepsia, 2013, 54, 1352-1359.	5.1	18

#	Article	IF	Citations
343	Retinal nerve fibre layer thinning is associated with drug resistance in epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 396-401.	1.9	18
344	Reasons for not having epilepsy surgery. Epilepsia, 2021, 62, 2909-2919.	5.1	18
345	Developments in antiepileptic drug therapy. Current Opinion in Neurology, 1994, 7, 131-139.	3.6	17
346	Levels of Stigmatization of Patients with Previously Untreated Epilepsy in Northern Ecuador. Neuroepidemiology, 1995, 14, 147-154.	2.3	17
347	The British Neurological Surveillance Unit: A Nation-Wide Scheme for the Ascertainment of Rare Neurological Disorders. Neuroepidemiology, 1995, 14, 182-187.	2.3	17
348	Remission of epilepsy. Lancet, The, 1995, 346, 1228.	13.7	17
349	The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: A study on levetiracetam. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 405-408.	2.0	17
350	Epilepsy perception amongst university students: a survey. Arquivos De Neuro-Psiquiatria, 2007, 65, 43-48.	0.8	17
351	Seasonality as a risk factor for sudden unexpected death in epilepsy: A study in a large cohort. Epilepsia, 2010, 51, 773-776.	5.1	17
352	Q8IYL2 is a candidate gene for the familial epilepsy syndrome of Partial Epilepsy with Pericentral Spikes (PEPS). Epilepsy Research, 2011, 96, 109-115.	1.6	17
353	Counterfeit antiepileptic drugs threaten community services in Guinea-Bissau and Nigeria. Lancet Neurology, The, 2015, 14, 1075-1076.	10.2	17
354	Value of video monitoring for nocturnal seizure detection in a residential setting. Epilepsia, 2016, 57, 1748-1753.	5.1	17
355	Incidence of sudden unexpected death in epilepsy in community-based cohort in China. Epilepsy and Behavior, 2017, 76, 76-83.	1.7	17
356	Partial epilepsy syndrome in a Gypsy family linked to 5q31.3â€q32. Epilepsia, 2009, 50, 1679-1688.	5.1	16
357	Cancer risk in people with epilepsy using valproate-sodium. Acta Neurologica Scandinavica, 2012, 125, 234-240.	2.1	16
358	Evolution of visual field loss over ten years in individuals taking vigabatrin. Epilepsy Research, 2013, 105, 262-271.	1.6	16
359	External Validation of a Prognostic Model for Seizure Recurrence Following a First Unprovoked Seizure and Implications for Driving. PLoS ONE, 2014, 9, e99063.	2.5	16
360	Complex SCN8A DNA-abnormalities in an individual with therapy resistant absence epilepsy. Epilepsy Research, 2015, 115, 141-144.	1.6	16

#	Article	IF	CITATIONS
361	Can natural ways to stimulate the vagus nerve improve seizure control?. Epilepsy and Behavior, 2017, 67, 105-110.	1.7	16
362	Long-interval intracortical inhibition as biomarker for epilepsy: a transcranial magnetic stimulation study. Brain, 2018, 141, 409-421.	7.6	16
363	Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center. Epilepsy and Behavior, 2018, 82, 81-86.	1.7	16
364	The yield of longâ€term electrocardiographic recordings in refractory focal epilepsy. Epilepsia, 2019, 60, 2215-2223.	5.1	16
365	Models of community-based primary care for epilepsy in low- and middle-income countries. Neurology, 2020, 94, 165-175.	1.1	16
366	A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis and Cannabinoid Research, 2021, 6, 528-536.	2.9	16
367	Assessing the role of rare genetic variants in drugâ€resistant, nonâ€lesional focal epilepsy. Annals of Clinical and Translational Neurology, 2021, 8, 1376-1387.	3.7	16
368	New drugs for epilepsy. Current Opinion in Neurology, 1998, 11, 141-148.	3.6	16
369	Sudden Death and Cardiac Arrythmia With Lamotrigine. Neurology, 2022, 98, .	1.1	16
370	Help-seeking strategies for epilepsy by previously untreated patients in northern Ecuador. Epilepsy Research, 1992, 11, 205-213.	1.6	15
371	Cancer mortality amongst people with epilepsy: A study of two cohorts with severe and presumed milder epilepsy. Epilepsy Research, 2009, 83, 190-197.	1.6	15
372	Marital adjustment for patients with epilepsy in China. Epilepsy and Behavior, 2013, 28, 99-103.	1.7	15
373	Comorbidity and premature mortality in epilepsy. Lancet, The, 2013, 382, 1618-1619.	13.7	15
374	The intriguing relationship between epilepsy and type 1 diabetes mellitus. Diabetologia, 2016, 59, 1569-1570.	6.3	15
375	Prone sleeping and SUDEP risk: The dynamics of body positions in nonfatal convulsive seizures. Epilepsy and Behavior, 2016, 62, 176-179.	1.7	15
376	Memory Rehabilitation Strategies in Nonsurgical Temporal Lobe Epilepsy. American Journal of Physical Medicine and Rehabilitation, 2017, 96, 506-514.	1.4	15
377	Seizures as a clinical manifestation in somatic autoimmune disorders. Seizure: the Journal of the British Epilepsy Association, 2019, 64, 59-64.	2.0	15
378	Neuroepidemiology in the United Kingdom Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 735-738.	1.9	14

#	Article	IF	CITATIONS
379	Towards a coherent public-health analysis for epilepsy. Lancet, The, 1999, 353, 1817-1818.	13.7	14
380	Mosaicism of a missense <i>SCN1A</i> mutation and Dravet syndrome in a Roma/Gypsy family. Epileptic Disorders, 2010, 12, 117-124.	1.3	14
381	Long term retention of retigabine in a cohort of people with drug resistant epilepsy. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 878-881.	2.0	14
382	Effect of oral contraceptives on lamotrigine levels depends on comedication. Acta Neurologica Scandinavica, 2014, 129, 393-398.	2.1	14
383	Health service provision for people with epilepsy in sub-Saharan Africa: A situational review. Epilepsy and Behavior, 2017, 70, 24-32.	1.7	14
384	Transcranial magnetic stimulation as a biomarker for epilepsy. Brain, 2017, 140, e18-e18.	7.6	14
385	Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy and Behavior, 2018, 80, 365-369.	1.7	14
386	Effects of the COVID-19 pandemic on medication adherence: In the case of antiseizure medications, A scoping review. Seizure: the Journal of the British Epilepsy Association, 2021, 93, 81-87.	2.0	14
387	Learning from the comorbidities of epilepsy. Current Opinion in Neurology, 2022, 35, 175-180.	3.6	14
388	Lamotrigine versus carbamazepine in epilepsy. Lancet, The, 1995, 345, 1300-1302.	13.7	13
389	Effects of AEDs on biomarkers in people with epilepsy: CRP, HbA1c and eGFR. Epilepsy Research, 2010, 91, 187-192.	1.6	13
390	Epilepsy as a systemic condition: Link with somatic comorbidities. Acta Neurologica Scandinavica, 2017, 136, 352-359.	2.1	13
391	Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis. Journal of Neurology, 2017, 264, 2378-2386.	3. 6	13
392	A homeâ€based, primaryâ€care model for epilepsy care in India: Basis and design. Epilepsia Open, 2019, 4, 264-274.	2.4	13
393	A descriptive survey of long-term residents with epilepsy and intellectual disability at the Chalfont Centre: is there a relationship between maladaptive behaviour and magnetic resonance imaging findings?. Journal of Intellectual Disability Research, 1999, 43, 475-483.	2.0	12
394	Importance of competing risks in the analysis of anti-epileptic drug failure. Trials, 2007, 8, 12.	1.6	12
395	Sodium valproate for epilepsy in rural China: An efficacy and safety assessment in primary care. Epilepsy Research, 2012, 102, 201-205.	1.6	12
396	Dysembryoplastic neuroepithelial tumors: A model for examining the effects of pathology versus seizures on cognitive dysfunction in epilepsy. Epilepsia, 2013, 54, 2214-2218.	5.1	12

#	Article	IF	CITATIONS
397	Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open, 2019, 4, 563-571.	2.4	12
398	FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force. Epilepsy Currents, 2021, 21, 150-153.	0.8	12
399	Classifying epilepsy pragmatically: Past, present, and future. Journal of the Neurological Sciences, 2021, 427, 117515.	0.6	12
400	Allopurinol as an add-on drug in the management of intractable epilepsy. Epilepsy Research, 1988, 2, 223-225.	1.6	11
401	Research in Epilepsy: Development Priorities for Developing Nations. Epilepsia, 2003, 44, 5-8.	5.1	11
402	Premature mortality in epilepsy: is it preventable?. Expert Review of Neurotherapeutics, 2011, 11, 767-770.	2.8	11
403	Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective. European Journal of Clinical Pharmacology, 2014, 70, 647-654.	1.9	11
404	HHV-7 in adults with drug-resistant epilepsy: A pathological role in hippocampal sclerosis?. Journal of Clinical Virology, 2014, 61, 387-392.	3.1	11
405	Guanidinoacetate methyltransferase (GAMT) deficiency: a rare but treatable epilepsy. Practical Neurology, 2017, 17, 207-211.	1.1	11
406	Neurocysticercosis as a probable risk factor for hippocampal sclerosis. Arquivos De Neuro-Psiquiatria, 2018, 76, 783-790.	0.8	11
407	Levetiracetam for prophylactic treatment of pediatric migraine: A randomized double-blind placebo-controlled trial. Cephalalgia, 2019, 39, 1509-1517.	3.9	11
408	The Use of Caffeine by People with Epilepsy: the Myths and the Evidence. Current Neurology and Neuroscience Reports, 2019, 19, 32.	4.2	11
409	Cardiac arrhythmias in Dravet syndrome: an observational multicenter study. Annals of Clinical and Translational Neurology, 2020, 7, 462-473.	3.7	11
410	Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. Epilepsy and Behavior, 2021, 115, 107602.	1.7	11
411	National epilepsy movement in Brazil. Arquivos De Neuro-Psiquiatria, 2007, 65, 55-57.	0.8	11
412	A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia, 2022, 63, 1563-1570.	5.1	11
413	Pros and Cons for the Development of New Antiepileptic Drugs. CNS Drugs, 2002, 16, 285-289.	5.9	10
414	Comorbidity as an epidemiological construct. Lancet Neurology, The, 2016, 15, 32.	10.2	10

#	Article	IF	CITATIONS
415	Has the Time Come to Stratify and Score SUDEP Risk to Inform People With Epilepsy of Their Changes in Safety?. Frontiers in Neurology, 2018, 9, 281.	2.4	10
416	SUDEP and seizure safety communication: Assessing if people hear and act. Epilepsy and Behavior, 2018, 86, 200-203.	1.7	10
417	Current and emerging drug therapies for the treatment of depression in adults with epilepsy. Expert Opinion on Pharmacotherapy, 2019, 20, 41-45.	1.8	10
418	Acute and late neurological complications of COVID19: the quest for evidence. Brain, 2020, 143, e99-e99.	7.6	10
419	Nifedipine as an add-on drug in the management of refractory epilepsy. Epilepsy Research, 1990, 6, 82-84.	1.6	9
420	Overtreatment with Antiepileptic Drugs. CNS Drugs, 1994, 2, 335-340.	5.9	9
421	An Audit of the Perceived Efficacy and Tolerability of Gabapentin Therapy in an Out-Patient Cohort with Chronic Epilepsy. European Neurology, 1999, 41, 111-113.	1.4	9
422	Assessing parents' attitudes towards ketogenic dietary therapies. Epilepsy and Behavior, 2014, 39, 1-5.	1.7	9
423	The ILAE classification of seizures and epilepsies: implications for the clinic. Expert Review of Neurotherapeutics, 2018, 18, 179-183.	2.8	9
424	A comparison between the 1981 and 2017 International League Against Epilepsy classification of seizure types based on an outpatient setting. Epileptic Disorders, 2018, 20, 257-264.	1.3	9
425	Marriage in epilepsy: The impact of the question in knowledge, attitude, and practice surveys. Epilepsy and Behavior, 2018, 85, 164-172.	1.7	9
426	Phase clustering in transcranial magnetic stimulation-evoked EEG responses in genetic generalized epilepsy and migraine. Epilepsy and Behavior, 2019, 93, 102-112.	1.7	9
427	A genomeâ€wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine. Epilepsia Open, 2019, 4, 102-109.	2.4	9
428	Genetic variants in incident SUDEP cases from a community-based prospective cohort with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 126-131.	1.9	9
429	Symptomatology of carbamazepineâ€and oxcarbazepineâ€induced hyponatremia in people with epilepsy. Epilepsia, 2021, 62, 778-784.	5.1	9
430	Deconstructing Dravet syndrome neurocognitive development: A scoping review. Epilepsia, 2021, 62, 874-887.	5.1	9
431	Association of consciousness impairment and mortality in people with COVIDâ€19. Acta Neurologica Scandinavica, 2021, 144, 251-259.	2.1	9
432	Parasites and epilepsy: Understanding the determinants of epileptogenesis. Epilepsy and Behavior, 2019, 92, 235-244.	1.7	9

#	Article	IF	CITATIONS
433	Using common genetic variants to find drugs for common epilepsies. Brain Communications, 2021, 3, fcab287.	3.3	9
434	Is the incidence of epilepsy falling in the UK?. Lancet, The, 1993, 342, 874.	13.7	8
435	Using Topiramate in Patients with Epilepsy: Practical Aspects. Canadian Journal of Neurological Sciences, 1998, 25, S16-S18.	0.5	8
436	Efficacy and Tolerability of the New Antiepileptic Drugs: Commentary on the Recently Published Practice Parameters. Epilepsia, 2004, 45, 1646-1649.	5.1	8
437	Antiepileptic drugs and suicidality. Neurology, 2010, 75, 300-301.	1.1	8
438	Focal epilepsy of probable temporal lobe origin in a Gypsy family showing linkage to a novel locus on 7p21.3. Epilepsy Research, 2011, 96, 101-108.	1.6	8
439	Knowledge and beliefs about epilepsy among people with and without epilepsy in urban Suriname. Epilepsy and Behavior, 2013, 29, 128-132.	1.7	8
440	Favourable response to ketogenic dietary therapies: undiagnosed glucose 1 transporter deficiency syndrome is only one factor. Developmental Medicine and Child Neurology, 2015, 57, 969-976.	2.1	8
441	Historical perspective: The British contribution to the understanding of neurocysticercosis. Journal of the History of the Neurosciences, 2019, 28, 332-344.	0.9	8
442	Neurological side effects of COVIDâ€19 vaccines are rare. Acta Neurologica Scandinavica, 2021, 144, 111-112.	2.1	8
443	Impact of the COVID-19 pandemic on people with epilepsy: Findings from the Brazilian arm of the COV-E study. Epilepsy and Behavior, 2021, 123, 108261.	1.7	8
444	Charles Bonnet syndrome: an example of cortical dissociation syndrome affecting vision?. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 134-134.	1.9	8
445	Levetiracetam: A new antiepileptic drug for the adjunctive therapy of chronic epilepsy. Drugs of Today, 2001, 37, 665.	2.4	8
446	Association of ultraâ€rare coding variants with genetic generalized epilepsy: A case–control whole exome sequencing study. Epilepsia, 2022, 63, 723-735.	5.1	8
447	Sudden Unexpected Death In Patients with Epilepsy. CNS Drugs, 2000, 13, 337-349.	5.9	7
448	Anticysticercal treatment and seizures in neurocysticercosis. Lancet Neurology, The, 2004, 3, 207-208.	10.2	7
449	Suicide risk in epilepsy: where do we stand?. Lancet Neurology, The, 2007, 6, 666-667.	10.2	7
450	Antiepileptic drugs and suicide risk: could stopping medications pose a greater hazard?. Expert Review of Neurotherapeutics, 2010, 10, 1775-1776.	2.8	7

#	Article	IF	CITATIONS
451	Web-search trends shed light on the nature of lunacy: Relationship between moon phases and epilepsy information-seeking behavior. Epilepsy and Behavior, 2013, 29, 571-573.	1.7	7
452	The performance of three mortality riskâ€adjustment comorbidity indices in a community epilepsy cohort. Epilepsia, 2015, 56, e68-72.	5.1	7
453	The SeLECT score is useful to predict post-stroke epilepsy. Lancet Neurology, The, 2018, 17, 395-396.	10.2	7
454	Validity of health insurance data to identify people with epilepsy. Epilepsy Research, 2018, 139, 102-106.	1.6	7
455	Ring Chromosome 17 Not Involving the Miller-Dieker Region: A Case with Drug-Resistant Epilepsy. Molecular Syndromology, 2018, 9, 38-44.	0.8	7
456	Oral health and dental status in people with epilepsy in rural China. Seizure: the Journal of the British Epilepsy Association, 2019, 65, 42-47.	2.0	7
457	In-hospital mortality of status epilepticus in China: Results from a nationwide survey. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 96-100.	2.0	7
458	Prevalence of MRI abnormalities in people with epilepsy in rural China. Neurology, 2020, 95, e1236-e1243.	1.1	7
459	Exploring epilepsy attendance at the emergency department and interventions which may reduce unnecessary attendances: A scoping review. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 39-46.	2.0	7
460	Temporal Lobe Epilepsy following Febrile Seizures: Unusually Prolonged Latent Periods. European Neurology, 2001, 46, 165-166.	1.4	6
461	The socioeconomic, cultural, and emotional implications of starting or withholding treatment in a patient with a first seizure. Epilepsia, 2008, 49, 35-39.	5.1	6
462	Network metaâ€analysis and the comparison of efficacy and tolerability of antiâ€epileptic drugs for treatment of refractory focal epilepsy. British Journal of Clinical Pharmacology, 2013, 76, 827-828.	2.4	6
463	Variants in KCNJ11 and BAD do not predict response to ketogenic dietary therapies for epilepsy. Epilepsy Research, 2015, 118, 22-28.	1.6	6
464	The topographical distribution of epileptic spikes in juvenile myoclonic epilepsy with and without photosensitivity. Clinical Neurophysiology, 2017, 128, 176-182.	1.5	6
465	Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Frontiers in Pharmacology, 2021, 12, 688386.	3.5	6
466	Spontaneously Fluctuating Motor Cortex Excitability in Alternating Hemiplegia of Childhood: A Transcranial Magnetic Stimulation Study. PLoS ONE, 2016, 11, e0151667.	2.5	6
467	Post traumatic epilepsy: there is still much to learn. Arquivos De Neuro-Psiquiatria, 2019, 77, 373-374.	0.8	6
468	Seizure outcomes in people with drug-resistant focal epilepsy evaluated for surgery but do not proceed. Epilepsy Research, 2021, 178, 106822.	1.6	6

#	Article	IF	CITATIONS
469	Effect of Anti-seizure Medications on Functional Anatomy of Language: A Perspective From Language Functional Magnetic Resonance Imaging. Frontiers in Neuroscience, 2021, 15, 787272.	2.8	6
470	Current Principles in the Management of Drug-Resistant Epilepsy. CNS Drugs, 2022, 36, 555-568.	5.9	6
471	Flumazenil as an anti-epileptic agent. Lancet, The, 1991, 337, 744.	13.7	5
472	Neurocysticercosis and epilepsy. Lancet, The, 1993, 341, 568.	13.7	5
473	Should Single Epileptic Seizures Be Treated?. European Neurology, 1994, 34, 186-192.	1.4	5
474	New antiepileptic drug trials in developing countries: are they necessary?. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 165-169.	2.0	5
475	Patients With Epilepsy Who Die Suddenly Do Not Always Have Cardiac Disease. Archives of Neurology, 1999, 56, 249.	4.5	5
476	A novel GEFS+ locus on 12p13.33 in a large Roma family. Epilepsy Research, 2011, 97, 198-207.	1.6	5
477	Sudden unexpected death in epilepsy: From animals to humans. Epilepsy and Behavior, 2012, 25, 54-55.	1.7	5
478	Epilepsy-related clinical characteristics and mortality: A systematic review and meta-analysis. Neurology, 2015, 84, 1823-1824.	1.1	5
479	Automated non-contact detection of central apneas using video. Biomedical Signal Processing and Control, 2020, 55, 101658.	5.7	5
480	Medication burden in epilepsy: Exploring the impact of non-epilepsy concomitant drugs load. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 104-110.	2.0	5
481	Traditional practices and perceptions of epilepsy among people in Roma communities in Bulgaria. Epilepsy and Behavior, 2020, 108, 107086.	1.7	5
482	Epilepsy knowledge, attitudes, and practices among primary healthcare providers in an Indian district. Epilepsy and Behavior, 2020, 104, 106899.	1.7	5
483	Îlpha 5 subunit-containing GABAA receptors in temporal lobe epilepsy with normal MRI. Brain Communications, 2021, 3, fcaa190.	3.3	5
484	Shared genetic basis between genetic generalized epilepsy and background electroencephalographic oscillations. Epilepsia, 2021, 62, 1518-1527.	5.1	5
485	Epidemiology of Epilepsy in Nigeria. Neurology, 2021, 97, e728-e738.	1.1	5
486	Demonstration project on epilepsy in Brazil - WHO/ILAE/IBE global campaign against epilepsy: a foreword. Arquivos De Neuro-Psiquiatria, 2007, 65, 1-4.	0.8	5

#	Article	IF	Citations
487	Risk of seizure recurrence in people with single seizures and early epilepsy – Model development and external validation. Seizure: the Journal of the British Epilepsy Association, 2022, 94, 26-32.	2.0	5
488	Sudden unexpected death in epilepsy. Risk factors, possible mechanisms and prevention: a reappraisal. Acta Neurologica Taiwanica, 2006, 15, 72-83.	0.3	5
489	The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. Epilepsy Research, 1990, 5, 235-239.	1.6	4
490	Effects of Epilepsy on Daily Functioning in Northern Ecuador: Summary of Findings of a Population-Based Research Project. Neuroepidemiology, 1992, 11, 180-189.	2.3	4
491	Stopping Drug Therapy in Epilepsy. Current Pharmaceutical Design, 2000, 6, 861-863.	1.9	4
492	Valporic acid and prion proteins. Annals of Neurology, 2003, 53, 688-689.	5.3	4
493	A Possible Role of the Thalamus in Some Cases of Sudden Unexpected Death in Epilepsy. Epilepsia, 2007, 48, 1036-1037.	5.1	4
494	Postictal sleep: Syncope or seizure?. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 350-351.	2.0	4
495	Sudden death in epilepsy. BMJ: British Medical Journal, 2011, 343, d7303-d7303.	2.3	4
496	Understanding of and attitudes towards people with epilepsy among community-based rehabilitation volunteers in Guinea-Bissau. Epilepsy and Behavior, 2013, 28, 196-200.	1.7	4
497	Reducing the risk of sudden death during epilepsy monitoring. Lancet Neurology, The, 2013, 12, 935-936.	10.2	4
498	Pediatric diagnosis not made until adulthood: A case of Wolfâ€"Hirschhorn syndrome. Gene, 2013, 512, 532-535.	2.2	4
499	Investigative practice into sudden death in epilepsy: A global survey. Acta Neurologica Scandinavica, 2019, 139, 476-482.	2.1	4
500	Comparing two classification schemes for seizures and epilepsy in rural China. European Journal of Neurology, 2019, 26, 422-427.	3.3	4
501	Risk factors for cancer and vascular deaths in patients with epilepsy in a community and a residential population: A case-controlled study. Journal of Epilepsy, 1996, 9, 23-26.	0.4	3
502	Antiepileptic drugs in developing countries. Lancet, The, 1998, 351, 1967.	13.7	3
503	Cost–effectiveness of carbamazepine in epilepsy. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 13-18.	1.4	3
504	Nurse Prescribing and the Management of Epilepsy. Epilepsia, 2006, 47, 669-671.	5.1	3

#	Article	IF	CITATIONS
505	The unknown cost of epilepsy misdiagnosis in England and Wales. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 377.	2.0	3
506	Asian promise: the state and future of collaborations in neuroscience. Nature Reviews Neuroscience, 2008, 9, 881-884.	10.2	3
507	Early treatment does not seem to affect the risk of mortality in epilepsy but the presence of comorbidity may. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 829-829.	1.9	3
508	Premature mortality in a Georgian cohort of people with epilepsy. Epilepsy Research, 2013, 107, 318-322.	1.6	3
509	Specialist management of routine dental procedures in adults with refractory epilepsy. British Dental Journal, 2014, 216, 403-407.	0.6	3
510	Commentary: <i>Epilepsia's</i> Survey on the Prevalence of Epilepsy. Epilepsia, 2015, 56, 166-166.	5.1	3
511	Promise and pitfalls of prognostic models for epilepsy surgery. Lancet Neurology, The, 2015, 14, 683-684.	10.2	3
512	Anti-epileptic drug changes and quality of life in the community. Acta Neurologica Scandinavica, 2016, 133, 421-426.	2.1	3
513	Cannabidiol in patients with treatment-resistant epilepsy. Lancet Neurology, The, 2016, 15, 544.	10.2	3
514	Age, Comorbidity, Frailty in Observational and Analytic Studies of Neurological Diseases. Frontiers of Neurology and Neuroscience, 2016, 39, 71-80.	2.8	3
515	Electro-clinical criteria and surgical outcome: Is there a difference between mesial and lesional temporal lobe epilepsy?. Acta Neurologica Scandinavica, 2017, 136, 708-714.	2.1	3
516	Smoking prevalence and seizure control in Chinese males with epilepsy. Epilepsy and Behavior, 2017, 73, 268-272.	1.7	3
517	Exposure to antiepileptic drugs in pregnancy: The need for a family factor framework. Epilepsy and Behavior, 2018, 86, 187-192.	1.7	3
518	Prevalence of epilepsy in rural China: a decreasing trend over 12 years. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1289-1291.	1.9	3
519	Mortality implications and factors associated with nonengagement in a public epilepsy care initiative in a transient population. Epilepsy and Behavior, 2020, 112, 107438.	1.7	3
520	Concerns about lamotrigine. Lancet Neurology, The, 2021, 20, 418-419.	10.2	3
521	Incidence and prevalence of epilepsy and associated factors in a health district in North-West Cameroon: A population survey. Epilepsy and Behavior, 2021, 121, 108048.	1.7	3
522	Epilepsy in a health district in North-West Cameroon: Clinical characteristics and treatment gap. Epilepsy and Behavior, 2021, 121, 107997.	1.7	3

#	Article	IF	Citations
523	Significant hypotension following buccal midazolam administration. BMJ Case Reports, 2010, 2010, bcr0920103371-bcr0920103371.	0.5	3
524	Reducing Sudden Unexpected Death in Epilepsy: Considering Risk Factors, Pathophysiology and Strategies. Current Treatment Options in Neurology, 2021, 23, 1.	1.8	3
525	Temporal trends in the epilepsy treatment gap in low- and low-middle-income countries: A meta-analysis. Journal of the Neurological Sciences, 2022, 434, 120174.	0.6	3
526	Assessing suicidal risk with antiepileptic drugs. Neuropsychiatric Disease and Treatment, 2010, 6, 613.	2.2	2
527	A fitful night's sleep. Practical Neurology, 2010, 10, 233-236.	1.1	2
528	Cost-Effectiveness of Brivaracetam Versus Other Antiepileptic Drugs Used as Adjunctive Treatment for Focal Seizures in the Uk: A Discrete Event Simulation Model. Value in Health, 2016, 19, A365.	0.3	2
529	Genes cut across systems. Neurology, 2016, 87, 1638-1639.	1.1	2
530	Trends in new-onset epilepsy â€" the importance of comorbidities. Nature Reviews Neurology, 2016, 12, 254-256.	10.1	2
531	Clinical characteristics of epilepsy in resourceâ€limited communities in Punjab, Northwest India. Epilepsia Open, 2020, 5, 582-595.	2.4	2
532	Translation and validation of an epilepsy-screening questionnaire in three Nigerian languages. Epilepsy and Behavior, 2021, 114, 107604.	1.7	2
533	Prognosis of adults and children following a first unprovoked seizure. The Cochrane Library, 0, , .	2.8	2
534	Vector-borne protozoal infections of the CNS: cerebral malaria, sleeping sickness and Chagas disease. Current Opinion in Neurology, 2021, 34, 439-446.	3.6	2
535	Reproducibility of Diagnostic Criteria for Ventricular Neurocysticercosis. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1952-1952.	1.4	2
536	Optimising epilepsy care throughout the Afghan refugee crisis. Lancet, The, 2021, 398, 1563.	13.7	2
537	Late-life terminal seizure freedom in drug-resistant epilepsy: "Burned-out epilepsy― Journal of the Neurological Sciences, 2021, 431, 120043.	0.6	2
538	Towards a pragmatic epilepsy classification: Future considerations. Seizure: the Journal of the British Epilepsy Association, 2020, 79, 95-96.	2.0	2
539	Ketoconazole in the treatment of cryptococcosis of the central nervous system. Arquivos De Neuro-Psiquiatria, 1991, 49, 208-210.	0.8	1
540	Can a patient-centred approach to epilepsy improve outcomes?. Progress in Neurology and Psychiatry, 2010, 14, 27-32.	0.9	1

#	Article	IF	CITATIONS
541	Epilepsy treatment: a paradigm shift is urgently need. Arquivos De Neuro-Psiquiatria, 2013, 71, 180-182.	0.8	1
542	Epileptic Seizures. , 2014, , 175-177.		1
543	Epilepsy; Epidemiology. , 2014, , 108-111.		1
544	In response: Multifactorial basis of epilepsy in patients with neurocysticercosis. Epilepsia, 2015, 56, 975-976.	5.1	1
545	Do clinicians use more question marks?. JRSM Open, 2015, 6, 205427041557902.	0.5	1
546	Cause of death and predictors of mortality in a community-based cohort of people with epilepsy. Neurology, 2016, 87, 852-853.	1.1	1
547	Transcranial magnetic stimulation as a biomarker of treatment response in children with epilepsy. Developmental Medicine and Child Neurology, 2020, 62, 770-770.	2.1	1
548	Metabolic issues in people with epilepsy. Epilepsy and Behavior, 2020, 108, 107081.	1.7	1
549	Prognostic factors predicting an unprovoked seizure recurrence in children and adults following a first unprovoked seizure. The Cochrane Library, 0, , .	2.8	1
550	Reduction of Retinal Thickness Ipsilateral to Hippocampal Sclerosis in Epilepsy. Frontiers in Neurology, 2021, 12, 663559.	2.4	1
551	Anticonvulsant Agents: Gabapentin and Pregabalin. , 2020, , 1-14.		1
552	The Chalfont Centre, Bucks, United Kingdom. Epilepsy and Behavior, 2017, 76, S50-S52.	1.7	1
553	Antiepileptic Drugs in Early Clinical Development. , 0, , 733-740.		1
554	The need for a pragmatic seizure classification in clinical trials. Epilepsia, 2022, 63, 1279-1280.	5.1	1
555	Cost of pre-surgical evaluation for epilepsy surgery: A single-center experience. Epilepsy Research, 2022, 182, 106910.	1.6	1
556	Hyperosmolar hyperglycaemic state causing atypical status epilepticus with hippocampal involvement. Practical Neurology, 2022, 22, 117-119.	1.1	1
557	THE CENTRAL NUCLEUS OF THE AMYGDALA IN SUDDEN UNEXPECTED DEATH IN EPILEPSY. Journal of Neuropathology and Experimental Neurology, 1998, 57, 497.	1.7	0
558	Transcultural Aspects of Epilepsy: A Forgotten Issue?. Epilepsia, 2003, 44, 1-1.	5.1	0

#	Article	IF	CITATIONS
559	Incidence and risk factors for sudden death in the Netherlands. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 559-560.	2.0	O
560	Epilepsy with centrotemporal spikes: A benign condition with potentially serious consequences. Epilepsy and Behavior, 2011, 20, 732.	1.7	0
561	Epilepsy; Comorbidity. , 2014, , 97-99.		0
562	Prevalence and potential causes of epilepsy in Nigeria. Epilepsy Research, 2014, 108, 1480.	1.6	0
563	Generic versus branded antiepileptic drug monotherapy for epilepsy. The Cochrane Library, 2015, , .	2.8	0
564	Comment: Improving the care of people with epilepsy and intellectual disabilities. Neurology, 2015, 85, 1519-1519.	1.1	0
565	Better meta-analytic methods, but best initial treatment for status epilepticus remains obscure. Neurology, 2015, 85, 1830-1831.	1.1	0
566	Reply. Annals of Neurology, 2016, 80, 954-954.	5.3	0
567	Reply. Annals of Neurology, 2017, 81, 474-475.	5.3	0
568	Epilepsy Comorbidity. Headache, 2017, , 41-63.	0.4	0
569	The comorbidities of epilepsy: A conceptual framework. , 2019, , 1-11.		0
570	018â€Optimising selection for epilepsy surgery. , 2021, , .		0
571	The impact of COVID-19 on epilepsy care: Perspectives from UK healthcare workers. Epilepsy and Behavior Reports, 2021, 16, 100487.	1.0	0
572	Identification of co-morbidities. Journal of the Neurological Sciences, 2021, 429, 117941.	0.6	0
573	Heart Rate Controversies in Epilepsy. Neurology, 2021, 97, 1103-1104.	1.1	0
574	A case of mistaken mesial temporal identity. BMJ: British Medical Journal, 2009, 338, b2258-b2258.	2.3	0
575	The increasing challenge of epilepsy in the elderly: shortening hospital admission. Arquivos De Neuro-Psiquiatria, 2020, 78, 669-671.	0.8	0
576	Paroxysmal Kinesigenic Dyskinesia Secondary to Brain Calcification with a Homozygous <scp>MYORG</scp> Mutation. Movement Disorders, 2022, 37, 233-235.	3.9	0

JW SANDER;

#	Article	IF	CITATIONS
577	Mortality associated with cysticercosis in a historical cohort from Britain. Arquivos De Neuro-Psiquiatria, 2022, 80, 248-254.	0.8	O
578	Secondary Paroxysmal Kinesigenic Dyskinesia with a <i>CASR</i> Mutation. Movement Disorders, 2022, 37, 643-644.	3.9	0
579	147†Long-term cenobamate retention in people with focal onset seizures: pooled data from open-label studies. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A55.3-A55.	1.9	O